Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines

Condition(s) studied

Study summary

Based on the trend that the incidence and mortality of cervical carcinoma among female cancers worldwide are increasing year by year, the investigators aim to develop a multi-epitope therapeutic vaccine capable of simultaneously activating humoral and cellular immune responses, which is achieved by fusing multiple T-cell epitope immunostimulatory proteins. To obtain information on functional T-cell epitopes to be included in the vaccine, the investigators conducted research starting from clinical cases. By collecting peripheral blood and cancerous tissues from clinical patients, the investigators isolated reactive T-cells and screened for information on T-cell epitopes of HPV antigens.

Eligibility

Primary outcome measure(s)

• The activity of T cell — one month
  The T cell activity exceeds 95%.

Trial sites (1)

More Anhui Provincial Hospital trials in China

Other trials for the same condition